pancreatic lesions
Conditions
Interventions
None listed
Sponsors
Okayama university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who visit the study institution between the date of approval by the head of the institution and June 30, 2028 Patients with pancreatic mass lesions who have both primary and metastatic lesions amenable to EUS-FNB and are scheduled to undergo comprehensive genomic profiling Patients from whom written informed consent can be obtained directly based on their own free will Patients aged 18 years or older at the time of consent
Exclusion criteria
Exclusion criteria: Patients with a performance status of 3-4 Patients with a bleeding tendency or a platelet count <50000 Patients receiving two or more antithrombotic agents Patients in whom no safe puncture route is available due to inability to visualize the lesion by EUS or due to intervening vessels Pregnant women Patients from whom written informed consent could not be obtained based on their own free will after receiving a full explanation of the study Patients deemed inappropriate for participation by the principal investigator or sub-investigators for any other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of specimens suitable for comprehensive genomic profiling will be compared between primary lesion specimens and metastatic lesion specimens. | — |
Secondary
| Measure | Time frame |
|---|---|
| Nucleic acid quantity,Tumor fraction,Section surface area,Core tissue length,Histology score,Technical success rate,Procedure related adverse events,Success rate of comprehensive genomic profiling | — |
Countries
Japan
Contacts
Public ContactYUKI FUJII
Okayama university hospital Gastroenterology
Outcome results
None listed